Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse CancersAaron M. Goodman, Razelle Kurzrock, Shumei Kato et al.|Molecular Cancer Therapeutics|2017Cited by 2.4k
PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomasAaron M. Goodman, Razelle Kurzrock, Sandip Pravin Patel|Nature Reviews Clinical Oncology|2016Cited by 464
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular eraGaurav Goyal, Eli L. Diamond, Aaron M. Goodman et al.|Blood|2020Cited by 397
Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor–Based ImmunotherapyYulian Khagi, Razelle Kurzrock, Aaron M. Goodman et al.|Clinical Cancer Research|2017Cited by 202
Common Sense Oncology: outcomes that matterChristopher M. Booth, Bishal Gyawali, Manju Sengar et al.|The Lancet Oncology|2023Cited by 101